Listen to Jacques as he recites tongue-twisters and updates you on the latest papers on amyloid-beta aggregation and toxicity in AD from August, 2020! We hope you like the episode, and if you're interested in amyloid pathology in AD, you might want to check out Jacques' last episode as well, episode 47 on APP processing.

The genetic landscape of Alzheimer's disease can be overwhelmingly broad. In this episode, Joseph is back to tell you about peer-reviewed research dealing with epigenetics, non-APOE related genetic pathways and a couple new genetic models that have been published in August 2020. Enjoy!

Join Anusha as she dives into papers published from August of 2020 that uncovers the effects of potential therapeutics in animal models for Alzheimer's Disease. In the first section, she covers research that targets multiple aspects of Alzheimer's pathology. In the second section, she focuses on research that aims to improve cognition and memory in animal models.

In this episode, Jacques updates you on the newest papers related to amyloid precursor protein processing in AD! You'll hear about the gamma secretase complex, the influence of accessory proteins on amyloidogenic cleavages of APP, and APP glycosylation patterns, among other interesting topics! Enjoy.

Bhumika is back to tell you more about the latest tools and techniques in imaging to diagnosis Alzheimer's disease from papers published in August 2020. This includes PET imaging, MRI, and machine learning techniques. If you're interested in this topic, make sure to check out Part 1, which is episode 43, as well. Enjoy!

In this episode, Naila takes you through peer-reviewed research published in August 2020, on the many non-pharmacological approaches to treating AD. She covers a lot of territory, from diet-based approaches, to exercise programs and their potential underlying mechanisms, to brain stimulation and some more esoteric treatments. This episode is sure to leave you with some food for thought.

You'll hear about some big topics in Alzheimer's disease research in this episode! Ellen covers all of the pre-clinical studies from August 2020 testing potential new treatments targeting neuroinflammation, oxidative stress, mitochondria, metabolism, and lipids. This is the second part of three pre-clinical testing episodes this month, check out episode #42 for part 1, and look out for part 3, coming soon!

Bhumika updates you on the new papers that use brain imaging to diagnose and study AD, in the first of two episodes on this topic! This includes new advances in MRI and PET imaging, and machine learning approaches. You'll hear about studies that looked at changes to functional connectivity, cortical thickness, and other neurological changes in AD, as well as new and improved methods to analyze brain imaging data. Stay tuned for more in Part 2 -- coming out on Sunday, Nov 8!

In Part 1 of the AD preclinical testing papers published in August 2020, Naila gets us started with some treatments that target the cholinergic system and synaptic function, tau phosphorylation and resulting pathology, and amyloid-beta mediated toxicity. Given these are some of the hallmarks of AD pathology, trying to prevent or reverse their effects could lead to promising therapeutic outcomes, which these papers first explore in animal models. Naila will also go over a couple miscellaneous — but equally interesting — papers, so stay tuned till the end!

Heather covers papers from August 2020 on the role of neuroinflammation and glial cells on Alzheimer's disease pathology. You'll hear about many papers studying the role of astrocytes and microglia in AD pathology, including how they interact with cell signalling pathways and AD-associated proteins such as amyloid and tau. She ends with a couple papers that aim to understand and/or model neuroinflammation in this disease. We hope you enjoy this episode of AMiNDR!